Boji Pharmaceutical-B (02659.HK) business operations are running normally. The controlling shareholder intends to increase its holdings and push for a buyback authorization, demonstrating long-term confidence.

Intelligence Financial APP News, Boji Pharmaceuticals-B (02659.HK) announced that the Board of Directors noted unusual fluctuations in the price and trading volume of the company's H shares recently. After conducting reasonable inquiries into the relevant circumstances, the Board of Directors confirmed that it is not aware of (i) any reasons causing the abnormal fluctuations in the price and trading volume of H shares; or (ii) any information that needs to be disclosed to avoid false market of the company's securities; or (iii) any insider information that needs to be disclosed under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance of Hong Kong. The Board of Directors also confirmed that the Group's business operations are normal, and there have been no significant changes in the Group's business operations and financial condition.